US FDA grants Fast Track Designation to Cu-67 SAR-bisPSMA for the treatment of metastatic CRPC patients February 25, 2025
ASCO GU 2025: New data for darolutamide confirm safety and improved efficacy across subgroups of patients with mHSPC February 19, 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals February 4, 2025
CAN-2409 Achieved Primary Endpoint in Ph 3 Prostate Cancer Trial, Showing Significantly Improved DFS December 18, 2024
Doses Selected for Ph 1b Expansion Trials Supported by Efficacy & Safety Profile Observed in Ph 1a Dose Escalation for JANX007 in metastatic CRPC December 10, 2024
Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer November 26, 2024
FDA Accepts Supplemental NDA for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic HSPC November 26, 2024
Truqap combination in PTEN-deficient mHSPC demonstrated statistically significant and clinically meaningful improvement in rPFS in CAPItello-281 Ph 3 trial November 26, 2024
ECLIPSE Trial Meets Primary Endpoint, Showing a Statistically Significant & Clinically Meaningful Benefit for Patients With PSMA+ve metastatic CRPC November 19, 2024
Ph 2 Study of Masofaniten + Enzalutamide in metastatic CRPC Patients terminated; efficacy signals observed will not achieve target product profile November 5, 2024
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture October 29, 2024
Updated Safety & Efficacy Data for Ph 1/2 Study of ONCT-534 for Treatment of R/R metastatic CRPC Announced October 29, 2024
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Ph 3 trial in patients with recurrence of prostate cancer October 22, 2024
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in OS compared to enzalutamide in patients with mCSPC October 8, 2024
Supplemental NDA submitted to FDA for darolutamide + ADT combo in patients with mHSPC October 1, 2024
Trials evaluating ONCT-534 in metastatic CRPC & ONCT-808 in BCL discontinued to explore strategic alternative September 18, 2024
Vobramitamab Duocarmazine Update Provided; treatment recently discontinued for TAMARACK metastatic CRPC patients who remained eligible for further dosing August 7, 2024
